Brief: InspireMD Presents Positive 30-Day Follow-Up Results From The C-Guardians U.S. IDE Clinical Trial At VIVA23

InspireMD

01/11/2023 18:21

Nov 1 (Reuters) - InspireMD Inc  NSPR.O :
    * INSPIREMD PRESENTS POSITIVE 30-DAY FOLLOW-UP RESULTS FROM
THE
C-GUARDIANS U.S. INVESTIGATIONAL DEVICE EXEMPTION (IDE) CLINICAL
TRIAL AT VIVA23
    * INSPIREMD INC - ANTICIPATES REPORTING PRIMARY ENDPOINT
RESULTS
FROM C-GUARDIANS IN SECOND HALF OF 2024 THAT MAY SUPPORT A PMA
APPLICATION
    * INSPIREMD - LOOK FORWARD TO REPORTING 12-MONTH RESULTS AS
WE
CONTINUE TO ADVANCE CGUARD EPS TOWARD POTENTIAL FDA APPROVAL IN
FIRST HALF OF 2025

Source text for Eikon:  ID:nGNX5tffj3 
Further company coverage:  NSPR.O 

 ((Reuters.Briefs@thomsonreuters.com;))